<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096017</url>
  </required_header>
  <id_info>
    <org_study_id>D589LC00002</org_study_id>
    <nct_id>NCT01096017</nct_id>
  </id_info>
  <brief_title>To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study</brief_title>
  <official_title>A Study to Investigate the Relative Efficacy of Terbutaline Turbuhaler® 0.4 mg and Salbutamol Pressurized Metered Dose Inhaler (pMDI) 200 μg - a Single Blind, Single Dose, Randomized, Crossover, Phase III Study in Japanese Adult Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single blind, single dose, crossover study to investigate the relative efficacy of
      terbutaline Turbuhaler® 0.4 mg in relation to salbutamol pressurized Metered Dose Inhaler
      (pMDI) 200 μg in Japanese adult asthmatic patients.The secondary objective of this study is
      to investigate safety of terbutaline Turbuhaler® 0.4 mg in Japanese adult asthma patients by
      means of adverse events (AEs) and vital signs (blood pressure, pulse rate). The subject
      population includes Japanese patients (16 years of age or older) with asthma who need
      treatment with inhaled Glucocorticosteroids (ICS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation</measure>
    <time_frame>At two visits during a maximum of 15 days. FEV1 timepoints: all time points t=5, 15, 30, 60, 120, 180 and 240 minutes.</time_frame>
    <description>FEV1 (Forced Expiratory Volume in 1 second) AUC 0-4 hours after drug inhalation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 (Forced Expiratory Volume in 1 Second) at 5 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</measure>
    <time_frame>At two visits during a maximum of 15 days</time_frame>
    <description>percent of pre-dose (ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (Forced Expiratory Volume in 1 Second) at 15 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</measure>
    <time_frame>At two visits during a maximum of 15 days</time_frame>
    <description>percent of pre-dose (ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (Forced Expiratory Volume in 1 Second) at 30 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</measure>
    <time_frame>At two visits during a maximum of 15 days</time_frame>
    <description>percent of pre-dose (ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (Forced Expiratory Volume in 1 Second) at 60 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</measure>
    <time_frame>At two visits during a maximum of 15 days</time_frame>
    <description>percent of pre-dose (ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (Forced Expiratory Volume in 1 Second) at 120 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</measure>
    <time_frame>At two visits during a maximum of 15 days</time_frame>
    <description>percent of pre-dose (ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (Forced Expiratory Volume in 1 Second) at 180 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</measure>
    <time_frame>At two visits during a maximum of 15 days</time_frame>
    <description>percent of pre-dose (ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (Forced Expiratory Volume in 1 Second) at 240 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</measure>
    <time_frame>At two visits during a maximum of 15 days</time_frame>
    <description>percent of pre-dose (ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum % Change in FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation</measure>
    <time_frame>At two visits during a maximum of 15 days</time_frame>
    <description>percent of pre-dose (ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation</measure>
    <time_frame>At two visits during a maximum of 15 days</time_frame>
    <description>Time to peak measurement of FEV1 (min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With % Change in FEV1 (Forced Expiratory Volume in 1 Second) &gt;15% Within 4 Hours After Drug Inhalation</measure>
    <time_frame>At two visits during a maximum of 15 days</time_frame>
    <description>Number of patients with % change in FEV1 &gt;15% within 4 hours after drug inhalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Change More Than or Equal to 15% (Time to Onset Response) Within 4 Hours After Drug Inhalation</measure>
    <time_frame>At two visits during a maximum of 15 days</time_frame>
    <description>Time to change more than or equal to 15% (time to onset response) within 4 hours after drug inhalation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒salbutamol pMDI 200 μg +placebo Turbuhaler®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbutaline Turbuhaler®</intervention_name>
    <description>0.4 mg, inhalation, single dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Bricanyl Turbuhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol pMDI</intervention_name>
    <description>200 μg, inhalation, single dose</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Saltanol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pMDI placebo pMDI</intervention_name>
    <description>Placebo pMDI 2 inhalations</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Turbuhaler®</intervention_name>
    <description>Placebo Turbuhaler 1 inhalation</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  On ICS for at least 3 months from Visit 2 and with a prescribed constant dose during
             the 4 weeks prior to Visit 2

          -  Forced Expiratory Volume in 1 Second (FEV1) of at least 50 % of predicted normal value
             pre-bronchodilator

          -  Reversible airway obstruction according to reversibility test performed at Visit 2,
             defined as an increase in Forced Expiratory Volume in 1 Second (FEV1) ≥12% relative
             baseline at 15-30 minutes after inhalation of in total 400 μg salbutamol

        Exclusion Criteria:

          -  Treatment with oral, parenteral or rectal GCS (Glucocorticosteroids)within 4 weeks or
             depot parenteral GCS (Glucocorticosteroids) within 3 months prior to Visit 2.

          -  Change in prescribed asthma medication due to exacerbation of asthma within 4 weeks
             prior to Visit 2 or being hospitalized due to exacerbation of asthma within 8 weeks
             prior to Visit 2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Andersson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <results_first_submitted>October 3, 2011</results_first_submitted>
  <results_first_submitted_qc>July 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2012</results_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Terbutaline</keyword>
  <keyword>Turbuhaler</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Asthma</keyword>
  <keyword>Japanese</keyword>
  <keyword>salbutamol</keyword>
  <keyword>Bricanyl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited at one clinic in Tokyo, Japan, between March and April 2010</recruitment_details>
      <pre_assignment_details>37 participants enrolled; 13 excluded (9 due to eligibility criteria not fulfilled and 4 for other reasons)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Salbutamol First, Then Terbutaline</title>
          <description>Salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI</description>
        </group>
        <group group_id="P2">
          <title>Terbutaline First, Then Salbutamol</title>
          <description>Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒Salbutamol pMDI 200 μg +placebo Turbuhaler®</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 1 - 14 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.7" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation</title>
        <description>FEV1 (Forced Expiratory Volume in 1 second) AUC 0-4 hours after drug inhalation</description>
        <time_frame>At two visits during a maximum of 15 days. FEV1 timepoints: all time points t=5, 15, 30, 60, 120, 180 and 240 minutes.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation</title>
          <description>FEV1 (Forced Expiratory Volume in 1 second) AUC 0-4 hours after drug inhalation</description>
          <units>milliLiters x minutes</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="617.56" lower_limit="352.57" upper_limit="974.45"/>
                    <measurement group_id="O2" value="634.64" lower_limit="356.68" upper_limit="1016.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (Forced Expiratory Volume in 1 Second) at 5 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
        <description>percent of pre-dose (ratio)</description>
        <time_frame>At two visits during a maximum of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Forced Expiratory Volume in 1 Second) at 5 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
          <description>percent of pre-dose (ratio)</description>
          <units>Percentage of Pre-Dose FEV1</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.58" lower_limit="102.80" upper_limit="137.95"/>
                    <measurement group_id="O2" value="112.80" lower_limit="100.00" upper_limit="134.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (Forced Expiratory Volume in 1 Second) at 15 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
        <description>percent of pre-dose (ratio)</description>
        <time_frame>At two visits during a maximum of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Forced Expiratory Volume in 1 Second) at 15 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
          <description>percent of pre-dose (ratio)</description>
          <units>Percentage of Pre-Dose FEV1</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.15" lower_limit="105.11" upper_limit="142.16"/>
                    <measurement group_id="O2" value="115.69" lower_limit="103.27" upper_limit="138.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (Forced Expiratory Volume in 1 Second) at 30 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
        <description>percent of pre-dose (ratio)</description>
        <time_frame>At two visits during a maximum of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Forced Expiratory Volume in 1 Second) at 30 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
          <description>percent of pre-dose (ratio)</description>
          <units>Percentage of Pre-Dose FEV1</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.42" lower_limit="103.28" upper_limit="147.32"/>
                    <measurement group_id="O2" value="117.02" lower_limit="99.59" upper_limit="139.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (Forced Expiratory Volume in 1 Second) at 60 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
        <description>percent of pre-dose (ratio)</description>
        <time_frame>At two visits during a maximum of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Forced Expiratory Volume in 1 Second) at 60 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
          <description>percent of pre-dose (ratio)</description>
          <units>Percentage of Pre-Dose FEV1</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.28" lower_limit="102.19" upper_limit="149.19"/>
                    <measurement group_id="O2" value="118.11" lower_limit="102.86" upper_limit="144.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (Forced Expiratory Volume in 1 Second) at 120 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
        <description>percent of pre-dose (ratio)</description>
        <time_frame>At two visits during a maximum of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Forced Expiratory Volume in 1 Second) at 120 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
          <description>percent of pre-dose (ratio)</description>
          <units>Percentage of Pre-Dose FEV1</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.54" lower_limit="97.45" upper_limit="149.73"/>
                    <measurement group_id="O2" value="119.79" lower_limit="103.27" upper_limit="150.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (Forced Expiratory Volume in 1 Second) at 180 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
        <description>percent of pre-dose (ratio)</description>
        <time_frame>At two visits during a maximum of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Forced Expiratory Volume in 1 Second) at 180 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
          <description>percent of pre-dose (ratio)</description>
          <units>Percentage of Pre-Dose FEV1</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.68" lower_limit="92.70" upper_limit="142.70"/>
                    <measurement group_id="O2" value="118.48" lower_limit="100.68" upper_limit="146.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (Forced Expiratory Volume in 1 Second) at 240 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
        <description>percent of pre-dose (ratio)</description>
        <time_frame>At two visits during a maximum of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Forced Expiratory Volume in 1 Second) at 240 Minutes After Inhalations of Study Drug as Percentage of Pre-dose</title>
          <description>percent of pre-dose (ratio)</description>
          <units>Percentage of Pre-Dose FEV1</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.59" lower_limit="87.96" upper_limit="132.67"/>
                    <measurement group_id="O2" value="117.05" lower_limit="97.96" upper_limit="139.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum % Change in FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation</title>
        <description>percent of pre-dose (ratio)</description>
        <time_frame>At two visits during a maximum of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum % Change in FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation</title>
          <description>percent of pre-dose (ratio)</description>
          <units>Percent change</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.62" lower_limit="105.11" upper_limit="149.73"/>
                    <measurement group_id="O2" value="121.43" lower_limit="105.31" upper_limit="150.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation</title>
        <description>Time to peak measurement of FEV1 (min)</description>
        <time_frame>At two visits during a maximum of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation</title>
          <description>Time to peak measurement of FEV1 (min)</description>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" lower_limit="5.00" upper_limit="180.00"/>
                    <measurement group_id="O2" value="120.00" lower_limit="5.00" upper_limit="240.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With % Change in FEV1 (Forced Expiratory Volume in 1 Second) &gt;15% Within 4 Hours After Drug Inhalation</title>
        <description>Number of patients with % change in FEV1 &gt;15% within 4 hours after drug inhalation.</description>
        <time_frame>At two visits during a maximum of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With % Change in FEV1 (Forced Expiratory Volume in 1 Second) &gt;15% Within 4 Hours After Drug Inhalation</title>
          <description>Number of patients with % change in FEV1 &gt;15% within 4 hours after drug inhalation.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Change More Than or Equal to 15% (Time to Onset Response) Within 4 Hours After Drug Inhalation</title>
        <description>Time to change more than or equal to 15% (time to onset response) within 4 hours after drug inhalation</description>
        <time_frame>At two visits during a maximum of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salbutamol pMDI</title>
            <description>200 μg, inhalation, single dose</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Turbuhaler®</title>
            <description>0.4 mg, inhalation, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Change More Than or Equal to 15% (Time to Onset Response) Within 4 Hours After Drug Inhalation</title>
          <description>Time to change more than or equal to 15% (time to onset response) within 4 hours after drug inhalation</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.36" spread="37.49"/>
                    <measurement group_id="O2" value="34.32" spread="40.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Salbutamol pMDI</title>
          <description>200 μg, inhalation, single dose.</description>
        </group>
        <group group_id="E2">
          <title>Terbutaline Turbuhaler®</title>
          <description>0.4 mg, inhalation, single dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

